Document:

exv10w3

Exhibit 10.3

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4)

and 203.406

Global Alliance Agreement

by and between

Uhde GmbH

and

Myriant Technologies LLC

 

			
	***	 	Confidential Treatment Requested

 

 

TABLE OF CONTENTS

	 	 	 	 	 

	Global Alliance Agreement
	 	 	1	 
	 
	Recitals
	 	 	1	 
	 
	A. Alliance Structure
	 	 	2	 
	 
	A.1 General Structure and Purposes of the Alliance
	 	 	2	 
	 
	A.1.1 Exclusive Alliance Arrangements
	 	 	2	 
	 
	A.2 Conduct and Governance of the Alliance
	 	 	3	 
	 
	A.3 Costs
	 	 	4	 
	 
	A.4 Exchange of Information
	 	 	4	 
	 
	B Joint Research and Development and Intellectual Property
	 	 	4	 
	 
	B.1 Rights to the Processes
	 	 	4	 
	 
	B.2 Intellectual Property Ownership
	 	 	5	 
	 
	B.2.1 Myriant Rights
	 	 	5	 
	 
	B.2.2 Uhde Rights
	 	 	5	 
	 
	B.3 Improvements and Working Results
	 	 	5	 
	 
	B.3.1. Myriant Improvements
	 	 	5	 
	 
	B.3.2 Uhde Improvements
	 	 	5	 
	 
	B.3.3 Joint Working Results
	 	 	6	 
	 
	B.4 Use and License Rights
	 	 	7	 
	 
	B.4.1 Myriant Grant of Use Rights to Uhde
	 	 	7	 
	 
	B.4.2 Uhde Grant of Use Rights To Myriant
	 	 	7	 
	 
	B.4.3 Uhde Grant of Uhde Process Plant Licenses
	 	 	7	 
	 
	B.4.4 Uhde Process License Fee
	 	 	7	 
	 
	B.4.5 Myriant Grant of Sublicense Rights
	 	 	8	 

 

			
	***	 	Confidential Treatment Requested

 

 

	 	 	 	 	 

	B.4.6 Uhde Grant of Sublicense Rights
	 	 	8	 
	 
	B.5 Application of Intellectual Property Rights and Maintenance
of Intellectual Property Rights
	 	 	8	 
	 
	B.5.1. Application for Intellectual Property Rights
	 	 	9	 
	 
	B.5.2. Costs
	 	 	9	 
	 
	B.5.3. Notice Rights
	 	 	9	 
	 
	B.5.4. Joint Filing of Application
	 	 	9	 
	 
	B.5.5. Separate Application of Either Party
	 	 	10	 
	 
	B.5.6 Maintenance of IP Rights
	 	 	10	 
	 
	B.5.7 Laws on Employees’ Invention
	 	 	10	 
	 
	B.5.8 Claiming of Employees’ Inventions
	 	 	10	 
	 
	B.6. Infringement of Intellectual Property Rights
	 	 	10	 
	 
	B.6.1 Information about Possible Infringements
	 	 	10	 
	 
	B.6.2 Defense
	 	 	11	 
	 
	B.6.3 Information about Charges and Mutual Support
	 	 	11	 
	 
	B.6.4 Charges by other Party
	 	 	11	 
	 
	B.7 Termination of the Agreement
	 	 	11	 
	 
	B.7.1 Ownership
	 	 	11	 
	 
	B.7.2 Continuing Rights to Working Results upon Termination
	 	 	12	 
	 
	B.7.3 Licensing of Joint Working Results
	 	 	12	 
	 
	B.7.4 Licensing of Separate IP Rights
	 	 	12	 
	 
	B.7.5 Maintenance of IP Rights
	 	 	12	 
	 
	B.7.6 Sale of IP Rights
	 	 	12	 
	 
	B.8 Compensation
	 	 	13	 

 

			
	***	 	Confidential Treatment Requested

 

 

	 	 	 	 	 

	C. Project Marketing 
	 	 	13	 
	 
	C.1 Activities
	 	 	13	 
	 
	C.2 Business Development Projects
	 	 	13	 
	 
	C.3 Proposal Development
	 	 	14	 
	 
	C.4 Proposal Costs
	 	 	16	 
	 
	C.5 [...***...]
	 	 	16	 
	 
	C.6 Process and Performance Guarantees
	 	 	16	 
	 
	D. Miscellaneous
	 	 	16	 
	 
	D.1 Effective Date
	 	 	16	 
	 
	D.2 Representation
	 	 	16	 
	 
	D.3 Confidentiality Agreement
	 	 	17	 
	 
	D.4 Term
	 	 	17	 
	 
	D.4.1 Termination of Agreement
	 	 	17	 
	 
	D.4.2 Termination with Immediate Effect
	 	 	17	 
	 
	D.5 Cooperation in the Light of Antitrust Laws
	 	 	18	 
	 
	D.6 Waiver of Terms
	 	 	18	 
	 
	D.7 Entire Agreement, Execution Costs, No Assignment
	 	 	18	 
	 
	D.8 Liability/Indemnity
	 	 	19	 
	 
	D.9 Governing Law/Mediation/Arbitration
	 	 	19	 
	 
	D.10 Amendments
	 	 	20	 
	 
	D.11 Severability
	 	 	20	 
	 
	D.12 Force Majeure
	 	 	20	 
	 
	D.13 Further Assurances
	 	 	21	 

 

			
	***	 	Confidential Treatment Requested

 

 

	 	 	 	 	 

	Annex 1-Definitions
	 	 	22	 
	 
	Exhibit A — Uhde Process License Fee Structure
	 	 	25	 
	Exhibit B — Engineering and Plant Proposal Fees
	 	 	26	 
	Exhibit C — [...***...]
	 	 	27	 

 

			
	***	 	Confidential Treatment Requested

 

 

Global Alliance Agreement

This Global Alliance Agreement (the “Agreement”) by and between Uhde GmbH, a German
company with its principal offices located at Friedrich-Uhde-Str. 15, 44141 Dortmund (hereinafter
referred to as “Uhde”) and Myriant Technologies LLC, a Delaware limited liability company,
with its principal offices located at 1 Pinehill Drive, Batterymarch Park II, Suite 301, Quincy, MA
02169 USA (hereinafter referred to as “Myriant”); each of Uhde and Myriant are singularly
also referred to herein as “Party” and jointly as “Parties” (certain capitalized terms shall have
the meaning ascribed to them as set forth in Annex 1 attached hereto and made a part hereof).

Recitals

WHEREAS, Uhde is an internationally recognized engineering and procurement company active in the
field of chemical, refining, petrochemical and other industrial plants, owns different proprietary
technologies and has extensive know-how and experience in the engineering, procurement and
construction of such technology related plants;

WHEREAS, Myriant is a science and technology company active in the development and
commercialization of next generation biorefineries for the production of bio-based chemicals and
fuels from renewable feedstocks, possesses the know-how to produce such fuels and chemicals, and is
developing a proprietary fermentation process for the production of Succinic Acid (herein referred
and hereinafter defined as the “Myriant Process”);

WHEREAS, Uhde and Myriant intend to exclusively cooperate in their research and development efforts
(the “Joint R&D”) hereunder to jointly develop and optimize the “Myriant Process” and the
“Uhde Process” (as defined herein) for the production of Succinic Acid in the “Pilot Plant” (as
defined herein) and future “Plants” (as defined herein), and the Parties shall license their
respective processes to each other on a royalty-free basis solely in furtherance of this objective;

WHEREAS, Uhde and Myriant intend to exclusively cooperate in their business development efforts
(the “Project Marketing”) to market, jointly develop, bid and execute “Projects” (as
defined herein) for the design, engineering, and procurement of commercial scale Succinic Acid
Plants worldwide (except for the United States) incorporating their respective processes;

WHEREAS, Myriant intends to use Uhde exclusively for engineering and as its engineering,
procurement and construction contractor for commercial-scale Succinic Acid plants worldwide (except
for the United States) incorporating their respective processes;

WHEREAS, Uhde has the know-how to isolate organic acids and has developed separation technology for
the isolation of Organic Acids, including Succinic Acid (herein referred to and hereinafter defined
as the “Uhde Process”);

WHEREAS, Uhde has licensed to “UCA” (as defined hereunder), an Affiliate of Uhde, the Uhde Process
for use in the United States and has granted it the right to license and sublicence the Uhde
Process, Uhde Improvements, and Joint Working Results

 

			
	***	 	Confidential Treatment Requested

1

 

solely for use within the United States to Myriant in a parallel agreement know as the “Alliance
Agreement between Uhde Corporation of America and Myriant Technologies LLC” dated as of September
11, 2009 (the “U.S. Alliance Agreement”);

WHEREAS, except as otherwise provided in the US Alliance Agreement, Uhde intends to licence such
Process to Myriant for use worldwide (except for the United States) in (i) any “Plants” (as defined
hereunder) for which Uhde shall be providing “process and performance guarantees” in accordance
with the license fees payable hereunder for such use; and (ii) those limited situations in which
Uhde will not be acting as the EPC or EP Plant contractor on mutually acceptable terms and
conditions to be agreed upon by Uhde and Myriant;

WHEREAS, UCA and Myriant are concurrently entering into the U.S. Alliance Agreement, with similar
terms and conditions valid for the United States only;

Now, therefore, in consideration of the foregoing and for good and other valuable consideration,
the mutual receipt and sufficiency of which is hereby acknowledged. the Parties hereto agree to the
following, which shall govern their cooperation:

	A.	 	ALLIANCE STRUCTURE
	 
	A.1 	 	General Structure and Purposes of the Alliance

a) The Alliance shall be based upon the Parties’ joint research and development efforts to
collaborate exclusively with each other to integrate and deploy the “Processes” (as
defined herein) in the Pilot Plant and future Plants (located outside of the United
States) during the “Term” (as defined herein) hereof. The Parties envision that they
shall first deploy the Processes in the proposed Pilot Plant, which shall be operated by
Myriant or its agents.

b) During the later stages of the Term, and subject to the conditions provided herein, the
Parties shall cooperate in “Project Marketing,” which shall include, without limitation,
the development of Projects and construction of Plants (located outside of the United
States) that Myriant or its Affiliates may (i) own, lease, operate or manage, (ii) supply
products to the end customer(s) and/or (iii) have the contractual relationship for such
supply of the Plant’s products to the end customer(s) and in which Uhde shall act as its
exclusive engineering, procurement and construction contractor.

c) Myriant and Uhde will each assign experienced personnel to the Alliance for the purpose
of advancing the purposes of the Alliance, including the Joint R&D and Project Marketing
as detailed herein. Myriant shall perform Project Marketing with regard to the end
customer(s) with reasonable technical assistance provided by Uhde and/or its Affiliates.

	A.1.1 	 	Exclusive Alliance Arrangements

a) Except as otherwise provided in Item C.2.e, Uhde or one of its Affiliates shall perform
its services as Myriant’s either exclusive engineering, procurement and construction
contractor (“EPC”) or, as the case may be, its exclusive engineering and
procurement contractor (“EP”) for any Plants

 

			
	***	 	Confidential Treatment Requested

2

 

located worldwide (except for the United States) during the Term hereof,
provided, however, that Myriant may, subject to the Item C.2.e,
individually pursue Projects only where (i) Uhde has affirmatively elected and advised
Myriant in writing of its decision not to pursue a Project jointly with Myriant; or (ii)
Uhde is unable to proceed on a Project because of its inability to provide Project process
and performance guarantees acceptable to the particular Project lender; further,
provided, however, that Myriant shall only proceed to use the Uhde Process
for such Projects in accordance with Item B.4.3 hereof and further,
provided, however, that the provision of [...***...]. Uhde, on the other
hand, shall not in any case during the Term hereof, pursue any Project without Myriant.

b) Myriant and its Affiliates, subject to the exceptions provided herein, will not enter
into discussions or negotiations with, solicit a proposal from, or consider any
unsolicited proposal from any other EP contractors for Projects. Uhde and its Affiliates,
subject to the exceptions provided herein, will not enter into discussions or negotiations
with, solicit a proposal from, or consider any unsolicited proposal from any other third
party for the realization of Projects; provided, however, that it is
expressly agreed between the Parties that Uhde remains free to provide and to actively
market the Uhde Process and, within the restrictions of Item B.4.5, Myriant Intellectual
Property Rights to any third party for plants worldwide (except for the United States)
that are not intended to produce Succinic Acid.

	A.2 	 	Conduct and Governance of the Alliance

	 	a)	 	The Parties will establish an Alliance steering committee with four (4) members with
equal representation by Myriant and Uhde (the “Steering Committee”).
	 
	 	b)	 	The Steering Committee shall convene in person, by videoconference or telephonically
on no less than a quarterly basis, and on shorter notice if circumstances dictate, to
review the performance of the Alliance, address any issues or disputes and take such other
actions as may advance the purposes of the Alliance. The Steering Committee shall have
such other responsibilities as set forth herein and shall also review and recommend
specific Projects for bid to the Parties, decide whether or not to bid for a specific
Project, and decide on further research and development work in connection with the
Processes.
	 
	 	c)	 	The Parties will establish a project team (the “Project Team”), with equal
representation by Myriant and Uhde. The Project Team’s basic functions shall be:

	 	i 	 	 development of the upstream and downstream Processes, including the
harmonization of the economics on both Parties’ sides,
	 
	 	ii 	 	 selection of technologies to be used for future Plants (located outside
of the United States), and
	 
	 	iii 	 	 oversight and coordination of design, construction and start-up of new
Plants (located outside of the United States).

 

			
	***	 	Confidential Treatment Requested

3

 

	A.3 	 	Costs
	 
	 	 	Except with respect to Uhde’s Project Proposal preparation costs as provided in Item C.4,
each Party shall bear its respective fees, costs, and expenses for all of the activities
of the Alliance, including for Joint R&D and Project Marketing. The Parties shall not
share any additional expense or cost in connection with efforts (e.g., for joint
developments, employment of external third parties etc.), unless specifically agreed to in
writing in advance by duly authorized representatives of the Parties.
	 
	A.4 	 	Exchange of Information
	 
	 	 	Each Party shall promptly inform and update each other of its progress in the research and
development of its respective Process, unless rights of third parties prevent such
disclosure of information. Further, the Parties shall collaborate with each other and
share their respective expertise to solve any problems or questions that may arise in the
course of the joint research and development work.
	 
	B	 	 JOINT RESEARCH AND DEVELOPMENT AND INTELLECTUAL PROPERTY
	 
	 	 	B.1 Rights to the Processes

	 	a)	 	Uhde. Uhde hereby represents and warrants to Myriant that as of the Effective
Date:

	 	i 	 	All requisite corporate action on the part of Uhde and on the part of
each of its officers and directors necessary for the authorization and execution of
this Agreement and the performance of its obligations hereunder has been taken.
	 
	 	ii 	 	 This Agreement is the legal, valid and binding obligation of Uhde,
enforceable against it in accordance with its terms.
	 
	 	iii 	 	 Uhde (a) has the rights to grant to Myriant the license rights set
forth in Section B herein and (b) has granted to UCA the necessary license rights
allowing UCA to grant to Myriant the required sublicenses under the U.S. Alliance
Agreement.
	 
	 	iv 	 	 No claim is pending, or to the best knowledge of Uhde, has been
threatened in writing against Uhde or its Affiliates challenging Uhde’s right of
use or ownership of the Uhde Process or to grant the licenses to the Uhde Process
pursuant to this Agreement or any other agreement licensing the Uhde Process to a
third party.

	 	b)	 	Myriant. Myriant hereby represents and warrants to Uhde that as of the
Effective Date:

	 	i 	 	 All requisite corporate action on the part of Myriant and on the part
of each of its officers and directors necessary for the authorization and execution
of

 

			
	***	 	Confidential Treatment Requested

4

 

	 	 	 	this Agreement and the performance of its obligations hereunder has been taken.
	 
	 	ii 	 	 This Agreement is the legal, valid and binding obligation of Myriant,
enforceable against it in accordance with its terms.
	 
	 	i 	 	 Myriant has the rights to grant to Uhde the license rights set forth in
Section B herein.
	 
	 	ii 	 	 No claim is pending, or to the best knowledge of Myriant, has been
threatened in writing against Myriant or its Affiliates challenging Myriant’s right
of use or ownership of the Myriant Process or to grant the licenses to the Myriant
Process pursuant to this Agreement.

	B.2 	 	Intellectual Property Ownership
	 
	B.2.1 	 	Myriant Rights
	 
	 	 	Myriant owns or is the licensee of all right, title and interest
in and to any pre-existing Intellectual Property Rights to the
Myriant Process, including any Prior IP Record. As between the
Parties, Myriant has the exclusive right, at its sole discretion
and expense, to apply for, register, maintain and enforce Patents
and other Intellectual Property Rights as it deems appropriate with
respect to any of the pre-existing Intellectual Property Rights it
has to the Myriant Process.
	 
	B.2.2 	 	Uhde Rights
	 
	 	 	Uhde owns or is the licensee of all right, title and interest in
and to any pre-existing Intellectual Property Rights to the Uhde
Process, including any Prior IP Record. As between the Parties,
Uhde has the exclusive right, at its sole discretion and expense,
to apply for, register, maintain and enforce Patents and other
Intellectual Property Rights as it deems appropriate with respect
to any of the pre-existing Intellectual Property Rights it has to
the Uhde Process.
	 
	B.3 	 	Improvements and Working Results
	 
	B.3.1. 	 	Myriant Improvements
	 
	 	 	Myriant Improvements, as such Improvements are described herein
and in any Prior IP Record, shall be the sole property of Myriant,
and all rights, including Intellectual Property Rights, shall vest
solely in Myriant. Accordingly, Myriant hereby licenses to Uhde
any and all right, title and interest in and to any Myriant
Improvements pursuant to this Item B.3.1 to the extent necessary
for Uhde to complete any of the tasks contemplated herein for the
Term of this Agreement. Uhde agrees to execute documents, render
such reasonable assistance, and take such other reasonable action
at Myriant’s expense as Myriant may reasonably request to apply
for, registered, perfect, confirm and protect any Myriant
Improvements it conceives under this Item B.3.1.
	 
	B.3.2 	 	Uhde Improvements

 

			
	***	 	Confidential Treatment Requested

5

 

	 	 	Uhde Improvements, as such Improvements are described herein and
in any Prior IP Record, shall be the sole property of Uhde, and all
rights, including Intellectual Property Rights, shall vest solely
in Uhde. Accordingly, Uhde hereby licenses to Myriant any and all
right, title and interest in and to any Uhde Improvements pursuant
to this Item B.3.2 to the extent necessary for Myriant to complete
any of the tasks contemplated herein for the Term of this
Agreement. Myriant agrees to execute documents, render such
reasonable assistance, and take such other reasonable action at
Uhde’s expense as Uhde may reasonably request to apply for,
registered, perfect, confirm and protect any Working Results it
conceives under this Item B.3.2.
	 
	B.3.3 	 	Joint Working Results
	 
	 	 	Joint Working Results shall be the joint property of both Parties,
and the rights for such Working Results shall vest jointly in both
Parties as provided herein (as defined hereinafter in Annex 1, the
“Joint Working Results”). Each Party agrees to grant, and hereby
does grant, usage rights to the other Party for any Joint Working
Result for any purposes contemplated under this Agreement.
Further, each Party shall not impair the other Party’s right to use
the Joint Working Results for any such purposes.
	 
	 	 	Notwithstanding the foregoing, the Steering Committee of the
Parties shall consider [...***...], including [...***...] between
the Parties, when determining [...***...]. [...***...].
	 
	 	 	Any allocation of license fees by the Steering Committee shall be
distributed between the Parties in proportion to each Party’s
contribution and in only one of the following three proportions:

	 	a)	 	[...***...]% to the Party judged by the
Steering Committee to have made the primary contribution to the Joint
Working Results (the “Primary Developer”) and 25% to the Party
judged by the Steering Committee to have made a lesser contribution
(the “Secondary Developer”);
	 
	 	b)	 	[...***...]% to each Party in the event that
both Parties are judged by the Steering Committee to have made equal
contributions or in the event that the Steering Committee cannot
determine within a reasonable time the respective contributions of the
Parties, or
	 
	 	c)	 	[...***...]% to the Primary Developer in the
event that the Steering Committee determines (1) that the Primary
Developer made an overwhelming contribution to the Joint Working
Results and/or (2) that the contribution consists solely of an Uhde
Improvement or a Myriant Improvement.

	 	 	The Steering Committee shall also consider the respective efforts that the Parties take in
the commercialization of the Joint Working Results when making any adjustments to the
foregoing allocation of the license fees. The

 

			
	***	 	Confidential Treatment Requested

6

 

	 	 	Steering Committee shall also determine whether to make any downward adjustments to the
Uhde License Fee charged by Uhde to Myriant as set forth in Exhibit A hereto based on any
contributions to the Joint Working Results made by Myriant.
	 
	 	 	In the event of a dispute in which one party claims to have made 100% of the contribution
and the other party claims to have made more than a de minimis contribution to the Joint
Working Results, the Parties shall refer the matter to the intellectual property rights
mediator as provided for in Item D.9.
	 
	B.4 	 	Use and License Rights
	 
	B.4.1 	 	Myriant Grant of Use Rights to Uhde
	 
	 	 	Subject to any existing third party licensing restrictions, Myriant
hereby grants to Uhde a worldwide (except for the United States),
non-exclusive, royalty-free right and license for Myriant’s
pre-existing Intellectual Property Rights, the Myriant Process, any
Myriant Improvement, and any Joint Working Results during the Term
solely for the Project’s purposes and development.
	 
	B.4.2 	 	Uhde Grant of Use Rights To Myriant
	 
	 	 	Subject to any existing third party licensing restrictions, Uhde
hereby grants to Myriant a worldwide (except for the United States),
non-exclusive, royalty-free right and license for Uhde’s
pre-existing Intellectual Property Rights, the Uhde Process, any
Uhde Improvement, and any Joint Working Results during the Term,
solely for the Project’s purposes and development.
	 
	B.4.3 	 	Grant of Uhde Process Licenses
	 
	 	 	Uhde hereby grants to Myriant (i) an exclusive, royalty-free right
and license to use the Uhde Process, any Uhde Improvement and any
Joint Working Result for use in the Pilot Plant, (ii) a worldwide
exclusive right and license to use the Uhde Process and any Uhde
Improvement for any Plants where Uhde is providing “process and
performance guarantees” in accordance with Item C.6, subject to the
license fee payable to Uhde in accordance with Item B.4.4, and (iii)
[...***...] the Uhde Process and any Uhde Improvement for Plants
where Uhde will [...***...] as the [...***...] because of either of
the conditions provided in Item A.1.1 (i) or (ii) hereinabove,
subject to terms and conditions to be agreed upon by and mutually
acceptable to Myriant and Uhde.
	 
	B.4.4 	 	Uhde Process License Fee
	 
	 	 	For the right to use the Uhde Process and any Uhde Improvement in accordance with Item
B.4.3(ii) above, Myriant shall pay to Uhde per Project in accordance with the license fee
structure described on Exhibit A attached hereto and made a part hereof. The license fee
shall be subject to adjustment in accordance with Item B.3 hereof. Notwithstanding
anything provided herein to the contrary, in no case shall Myriant be required to pay
duplicate royalties for one and the same Project to both Uhde and UCA for

 

			
	***	 	Confidential Treatment Requested

7

 

	 	 	the right to use, license, or sublicense Uhde and/or UCA’s Intellectual Property Rights.
	 
	B.4.5 	 	Myriant Grant of Sublicense Rights
	 
	 	 	Myriant hereby grants Uhde a perpetual, non-exclusive, worldwide
(except for the United States) right and license, including the
right to grant and authorize sublicenses, under Myriant Intellectual
Property Rights other than to its Joint Working Results, including
rights in and to the Myriant Process and any Myriant Improvement;
provided that Uhde obtains prior written approval from Myriant, such
approval which may be granted at Myriant’s sole discretion, and
provided further that for each particular sublicense, the Steering
Committee shall agree on the principal terms and conditions of any
such sublicense, including the terms and conditions and the royalty
rate. With respect to Joint Working Results, Myriant hereby grants
Uhde a perpetual, non-exclusive right and license outside the United
States, including the right to grant and authorize [...***...],
under Myriant Intellectual Property Rights to such Joint Working
Results; provided that for each particular [...***...], the Steering
Committee shall agree on the principal terms and conditions of each
such [...***...], including the term of the royalty rate.
	 
	B.4.6 	 	Uhde Grant of Sublicense Rights
	 
	 	 	Uhde hereby grants Myriant a perpetual, non-exclusive, worldwide
(except for the United States) right and license, including the
right to grant and authorize sublicenses, under Uhde Intellectual
Property Rights other than to its Joint Working Results, including
rights in and to the Uhde Process and any Uhde Improvement, provided
that Myriant obtains prior written approval from Uhde for any
sublicenses (which shall not be unreasonably withheld or delayed
where Uhde is not acting as either the EPC or the EP contractor in
accordance with Item A.1.1(i) and (ii)), and further provided that
for each particular sublicense, the Steering Committee shall agree
on the principal terms and conditions of each such sublicense,
including the term and the royalty rate. In the case where Uhde is
not acting as the EPC or EP contractor in accordance with Item
A.1.1(i) and (ii), if the Parties are unable to agree on such terms
and conditions, then the matter may be referred to the intellectual
rights mediator for resolution as provided for in Item D.9. With
respect to Joint Working Results, Uhde hereby grants Myriant a
perpetual, non-exclusive right and license outside the United
States, including the right to grant and authorize [...***...],
under Uhde Intellectual Property Rights to such Joint Working
Results; provided that for each particular [...***...], the Steering
Committee shall agree on the principal terms and conditions of each
such [...***...], including the term and the royalty rate.
Notwithstanding anything provided herein to the contrary, in no case
shall Myriant be required to pay royalties to both Uhde and UCA for
the right to use, license, or [...***...] the same Intellectual
Property Rights of UCA under the US Alliance Agreement.
	 
	B.5 	 	Application of Intellectual Property Rights and Maintenance of
Intellectual Property Rights

 

			
	***	 	Confidential Treatment Requested

8

 

	B.5.1 	 	Application for Intellectual Property Rights
	 
	 	 	In the case that any development or a part of it which is entered
into the project by either Party, and which this Party developed
without reference to information of the other Party, can be
protected by Intellectual Property Rights, either Party shall
promptly enter such application to the respective authorities.
Either Party shall refrain from applying for any Intellectual
Property Rights for such development or information or parts of such
development or information which is provided by the other Party,
unless agreed to by both Parties and filed jointly under the
provisions of Item B.5.4.
	 
	B.5.2 	 	Costs
	 
	 	 	The costs for the application, receipt and maintenance of such
Intellectual Property Rights shall be borne by that Party that
applies for such rights.
	 
	B.5.3 	 	Notice Rights
	 
	 	 	The Party applying for any Intellectual Property Rights (the
“Applying Party”) shall inform the other Party (the “Non-Applying
Party”) immediately after applying, filing or registration of such
rights so as to give the other Party the opportunity to have its
business interests addressed by having the Applying Party add any
issues to the application that the Non-Applying Party may request to
have its business interests sufficiently covered. An Applying Party
shall also notify the Non-Applying Party if it intends to disregard,
diminish or otherwise restrict the scope of any claims to
Intellectual Property Rights in an application, filing or
registration process for any Intellectual Property Rights. The
Applying Party shall notify the Non-Applying Party for any such
action in the course of a grant, appeal or complaint process, if the
interests of the other Non-Applying Party may be, or are affected
by, such action.
	 
	B.5.4 	 	Joint Filing of Application
	 
	 	 	In the case of filing for Intellectual Property Rights according to
Item B.5.1 above the Parties shall jointly file the application for
having their Intellectual Property Rights registered. The costs for
such joint application, filing and/or registration shall be borne by
both Parties jointly and equally. With respect to any such filing,
the Parties shall mutually decide on the territorial/regional extent
of their application. If either Party is explicitly not interested
in applying for Intellectual Property Rights in any country or
region, the other Party shall be free to apply for Intellectual
Property Rights in that country/region without the participation of
the Party forgoing the opportunity to apply for such Rights. In such
a case and for such countries/regions, the Applying Party shall be
the sole possessor of the Intellectual Property Rights it applies
for and shall bear all additional costs arising out of any such
applications. The Non-Applying Party shall nevertheless have a
non-exclusive right to use such Intellectual Property Rights.

 

			
	***	 	Confidential Treatment Requested

9

 

	B.5.5 	 	Separate Application of Either Party
	 
	 	 	If a Party is not interested in applying for Intellectual Property
Rights, it shall give the other Party sufficient time to apply for
and obtain such Intellectual Property Rights at any place the
Applying Party contemplates making a filing related to its
Intellectual Property Rights. Upon receipt of such notice, the
Applying Party shall have the right, at its own cost, to assume the
prosecution and maintenance with respect to such Intellectual
Property Right, as applicable, and the Non-Applying Party shall
assign all of its right, title and interest in and to such
Intellectual Property Right, or claim thereof, as applicable, to the
Applying Party. The Applying Party shall bear all costs and
obligations for any separate applications that it may elect to make
pursuant to this Item B.5.5.
	 
	B.5.6 	 	Maintenance of IP Rights
	 
	 	 	If a Party is not interested in maintaining an Intellectual Property
Right that it possesses, it shall give the other Party sufficient
time to analyze and consider whether it wishes to have the
Intellectual Property Right assigned or otherwise transferred to it
so that it may maintain the Intellectual Property Right. In the
event that the other Party decides to maintain such an Intellectual
Property Right, the Party in possession of such Intellectual
Property Right shall transfer it to the other Party.
	 
	B.5.7 	 	Laws on Employees’ Invention
	 
	 	 	The Parties shall claim inventions of their employees conceived in
the course of the collaboration contemplated by this Agreement
according to the national laws applicable to employees’ invention as
defined in Item D.9 hereunder, unless both Parties declare that they
do not have any interest in the invention.
	 
	B.5.8 	 	Claiming of Employees’ Inventions
	 
	 	 	Either Party shall arrange to obtain all rights, title and interest
in and to any inventions made by its own employees on its own. The
respective Party shall, however, coordinate with the other Party, if
such invention falls under the provisions of Items B.3.1, B.3.2, or
B.3.3. In the case of Working Results, the Party whose employees did
not contribute any inventions shall compensate the other Party for
making use of inventions made by the other Party’s employees
according to the applicable national laws governing rights with
respect to employees’ inventions.
	 
	B.6 	 	Infringement of Intellectual Property Rights
	 
	B.6.1 	 	Information about Possible Infringements
	 
	 	 	The Parties shall inform each other without undue delay about any
suspected infringement of Intellectual Property Rights that may be
subject to or in connection with anything provided for under this
Agreement.

 

			
	***	 	Confidential Treatment Requested

10

 

	B.6.2 	 	Defense
	 
	 	 	The owner or licensor of the Intellectual Property Right that a
third party allegedly infringes shall defend its Intellectual
Property Right against such third party infringement. The Parties
shall coordinate their proceedings in such matters.
	 
	 	 	In the case that legal proceedings are taken against it, the Party
defending itself shall bear all costs related to its defense. The
costs incurred by a Party joining as a third-party defendant to such
a proceeding shall be borne by the Party thus joining.
	 
	B.6.3 	 	Information about Charges and Mutual Support
	 
	 	 	In the event a Party is alleged to have breached an Intellectual Property Right that is
related to or based on this Agreement, the allegedly infringing Party shall immediately
inform the other Party thereof. The other Party shall be entitled to join any legal
proceedings in the defense of such claims by third parties. The Party not addressed by
such claim shall be obliged to reasonably cooperate with the other Party.
	 
	B.6.4 	 	Charges by other Party
	 
	 	 	If (i) either Party, or its Affiliates, make or file a claim against the other Party for a
breach of Intellectual Property Rights that are subject to or arise in connection with
this Agreement, or (ii) a Party, or its Affiliates, support a third party in making a
claim for breach of Intellectual Property Rights, the other Party may terminate this
Agreement with immediate effect.
	 
	 	 	Upon effectiveness of the termination under this Item the Parties lose the right to use
the Intellectual Property Rights of the other Party as well as the Working Results of the
other Party. The terminating Party has to return to the other Party all information, such
as but not limited to documents, data, specimen etc. referring to the said Intellectual
Property Rights and for those Working Results which are the sole property of the other
Party, as far and if the terminating Party has received any of these from the other Party.
	 
	 	 	The Joint Working Results shall be dealt with according to Item B.7.3 below.
	 
	B.7 	 	Termination of the Agreement
	 
	B.7.1 	 	Ownership
	 
	 	 	Upon effectiveness of termination of this Agreement, each Party shall remain owner of its
pre-existing Intellectual Property Rights, including any Prior IP Record, as provided for
in Items B.2.1 and B.2.2.

 

			
	***	 	Confidential Treatment Requested

11

 

	B.7.2 	 	Continuing Rights to Joint Working Results upon Termination
	 
	 	 	In the event of the election by both Parties to mutually terminate this Agreement prior to
the expiration of the Term, the Steering Committee shall meet to determine in good faith
the equitable treatment and disposition of the continuing rights of the Parties to any
Joint Working Results. The Steering Committee shall consider all relevant factors in
making any allocations of the of the Joint Working Results, current research and
development program of each Party incorporating the Joint Working Results, existing and
future potential royalty streams, pending and prospective patent applications. In the
event that the Steering Committee is unable to reach a determination of the Parties’
respective rights, the Parties may refer the issue to the intellectual property mediator
for resolution pursuant to the mechanism provided for in Item D.9. In the event of a
termination of this Agreement arising out of a material breach by one of the Parties
hereto, the Party who commits the material breach shall forfeit all rights it may have to
any Joint Working Results. If the Parties dispute the existence of a material breach, the
Parties shall refer the matter to arbitration as provided for in Item D.9.
	 
	B.7.3 	 	Licensing of Joint Working Results
	 
	 	 	In the event that this Agreement is terminated for any reason other
than a material breach, each Party shall grant to the other Party a
non-exclusive and sub-licensable right to use any Joint Working
Results so as to allow for either Party to continue the research,
development and marketing of any Joint Working Results; provided,
however, that for each particular sublicense, the Steering Committee
shall agree on the principal terms and conditions of each such
sublicense, including the term and the royalty rate. If the Parties
are unable to agree on such terms and conditions, then the matter
may be referred to the intellectual rights mediator for resolution
as provided for in Item D.9.
	 
	B.7.4 	 	Licensing of Separate IP Rights
	 
	 	 	The Steering Committee shall negotiate and agree on reasonable
license fees and other terms and conditions for those Intellectual
Property Rights that are the sole property of either Party and to
which the other Party requires access to continue its research and
marketing activities.
	 
	B.7.5 	 	Maintenance of IP Rights
	 
	 	 	Upon effectiveness of the termination, neither Party shall be
obliged to maintain its patents or patent applications, irrespective
of these being joint or own patents or patent applications.
	 
	B.7.6 	 	Sale of IP Rights
	 
	 	 	If either Party decides to sell any of its Intellectual Property Rights, the other Party
shall have a pre-emptive right to buy this Intellectual Property Right from that Party at
a reasonable price to be negotiated between the Parties in good faith. The other Party may
consider such pre-emptive right for at least

 

			
	***	 	Confidential Treatment Requested

12

 

	 	 	twenty-eight (28) days upon receipt of an offer before losing its right of decision on the
offer. Any times of negotiation between the Parties shall toll this time limit.
	 
	B.8 	 	Compensation
	 
	 	 	Neither Party shall receive from the other Party compensation for
cooperating in the tasks contemplated by this Agreement. License fees
or any other forms of payment provided for separately under this
Agreement shall not be covered by this provision.
	 
	C.	 	PROJECT MARKETING
	 
	C.1 	 	Activities

	 	a)	 	Upon the commencement of first commercial production of Succinic Acid from any Plant
(located outside of the United States) constructed hereunder, or at such earlier time as
determined by the Steering Committee, the Steering Committee will assume the oversight and
coordination of proposal development and Project marketing activities for the Alliance
(herein “Project Marketing”). The marketing activities shall include, without
limitation, the following:

	 	(i)	 	determination as to which Projects it should market the Processes and to
whom it should do so; and
	 
	 	(ii)	 	facilitation of the exchange of Project and Plant opportunity lists between
the Parties (for Plants outside of the United States);

	 	b)	 	The Parties will agree on forms of contract with mutually acceptable terms and
conditions for the provision of EPC services.
	 
	 	c)	 	The Parties shall work together in good faith to explore all related areas of
potential synergy that may enhance the ability of the Parties to win bids for and execute
Projects.

	C.2 	 	Business Development Projects

	 	a)	 	The Parties shall collaborate on the development of Projects and provide each other
with necessary sales and business development support, including, without limitation,
joint communication with investor(s) for Projects, Plants (located outside of the United
States), process case analysis, budgetary and/or firm proposals and, to the extent
required, any Intellectual Property Rights necessary for the preparation of any Project
proposal.
	 
	 	b)	 	The Parties shall share their respective lists of opportunities related to Projects
and Plants with each other (for Plants outside of the United States).
	 
	 	c)	 	The Parties shall convene on a regular monthly basis (or other frequency as mutually
agreed to by the Parties) in person, by videoconference or telephonically to review the
new business opportunities, prioritize such

 

			
	***	 	Confidential Treatment Requested

13

 

	 	 	 	opportunities, inform each other about the current status of potential or existing Projects
and other new Project opportunities that have come to the knowledge of a Party, and to
develop strategies for jointly developing and acquiring such targeted opportunities.
	 
	 	d)	 	If either Party has identified a prospective Project, such Party shall refer the
prospective Project to the other Party for mutual consideration regarding the submission
of a proposal for such Project. The Parties shall jointly determine whether to pursue the
Project or not. A decision to pursue a Project must be by mutual agreement and jointly
confirmed in writing.
	 
	 	e)	 	In those cases where Uhde will [...***...] as the [...***...] for the reasons
specified in Item [...***...], Myriant [...***...] such a Project with a [...***...]
without restriction subject to Item B.4.3 hereof, provided, however, that Myriant shall
first confer with Uhde as to the [...***...] to assure that there are no confidentiality
or technology transfer concerns in connection with licensing the Uhde Process for use in
such Project. Myriant shall respect Uhde’s concern in making the [...***...].
	 
	 	f)	 	If required by lenders or by applicable market conditions, Uhde may offer and perform
services to Myriant based on United States Dollars. However, should Uhde have parts of its
services performed based on Euro, to enable both Parties to take advantage of fluctuating
rates of exchange or to avoid their exposure during the validity period of any proposal,
Uhde shall fix the rate of exchange for the calculation of the respective Euro portion at
the rate valid as of the date of the proposal. Should there be an increase or decrease of
the exchange rate at the date of effectiveness of a contract based on such proposal, the
USD-Price shall be fixed in the contract by calculating this price according to the new
exchange rate quoted by the European Central Bank as official rate of exchange valid at
the date of such effectiveness.
	 
	 	g)	 	If an identified Project requires the Parties to enter into a joint venture with any
third party due to national or other legal restrictions, the Parties shall discuss and
agree on the appropriate structure on a case by case basis.

	C.3 	 	Proposal Development
	 
	 	 	The Parties recognize that during the Plant Proposal development process, Myriant may
require budgetary cost and performance information for its own evaluation of the
development of budgetary proposals for Myriant’s own investment purposes, an end customer
or a third party investor or lender for a Plant (located outside of the United States),
and/or for screening of process and/or supply concepts. Uhde agrees to provide at its own
cost the necessary sales and business development support for such budgetary estimates as
outlined below. Myriant will provide a functional specification for each opportunity,
which will include, at a minimum: product requirements, feed information, utility
availability, economic evaluation criteria, and preliminary site information. Uhde shall
provide the following deliverables for each budgetary proposal opportunity:

	 	•	 	Preliminary Process Flow Diagram (PFD) with its associated material balance;

 

			
	***	 	Confidential Treatment Requested

14

 

	 	•	 	Consumption/utility estimates; and
	 
	 	•	 	Budgetary cost estimates (+/-30%).

	 	 	If Myriant asks for a firm proposal by Uhde, or if the Parties agree to jointly develop a
Project proposal for an end customer or investor or lender, they will agree on the scope
of work, the design basis of the Project, and the process concept as well as the
time-schedule for the proposal deliverables. In certain countries, Uhde’s project scope
of work will typically be an engineering/procurement approach (EP). In case of an EP
approach, if required for financing purposes, UCA is willing to act as a subcontractor to
the construction or prime contractor.
	 
	 	 	Myriant will provide a detailed specification for each Project proposal. This
specification will include, at a minimum:

	 	•	 	a process functional definition —including product requirements, feed
information, utility availability, emission limitations, and economic evaluation
criteria;
	 
	 	•	 	a technical specification — including equipment design criteria, instrumentation
requirements, and applicable codes and standards; and
	 
	 	•	 	an execution specification — including scope of work matrix, communication
requirements, schedule requirements, and site information.

	 	 	The schedule for the Uhde deliverables shall be agreed on by and between the Parties for
each Project proposal. The following Uhde deliverables are typical and depend on Uhde
Scope:

	 	a)	 	Technical Deliverables:

	 	•	 	Process flow diagram (PFD) with process description;
	 
	 	•	 	Heat and material balance;
	 
	 	•	 	Preliminary utility consumption (amounts and requirements); and
	 
	 	•	 	Preliminary time schedule.

	 	b)	 	Commercial Deliverables:

	 	•	 	Cost estimate (for Uhde scope only):

	 	o	 	Engineering services;
	 
	 	o	 	Equipment incl. transportation;
	 
	 	o	 	Bulk materials;
	 
	 	o	 	Site advisory services; and

	 	•	 	Terms and conditions in accordance with market norms for EPC contracts,
including indemnification, insurance, and market-based liquidated damages (which
Myriant believes may range of up to [...***...] of the Plant EPC contract
price), in all cases, subject to the approval of the Board of Directors of Uhde.

 

			
	***	 	Confidential Treatment Requested

15

 

	C.4 	 	Proposal Costs
	 
	 	 	Notwithstanding anything contained herein to the contrary, Uhde will be reimbursed by
Myriant for the reasonable costs incurred in the preparation of any proposals requested by
Myriant for any Project or Plant (located outside of the United States) in accordance with
Exhibit B attached hereto and made a part hereof; provided, however, that in no
event shall Myriant be required to pay both Uhde and UCA under the US Alliance Agreement
for the same items or service.
	 
	C.5	 	 [...***...].
	 
	 	 	Uhde shall either quote a lump sum price for its services and supplies for a firm proposal
to Myriant, or, if requested by Myriant, provide such lump sum price on basis of
[...***...], the principles of which are set forth on Exhibit C attached hereto and made a
part hereof.
	 
	C.6 	 	Process and Performance Guarantees
	 
	 	 	If an identified Project requires the provision of process and performance guarantees for
the Processes by Uhde, the Parties shall discuss and negotiate in good faith upon the
structure, conditions and form of such guarantees in consideration of the reliability of the
Processes at the time of such requirement. The Parties acknowledge and have discussed in
detail the provision that any process and/or performance guarantees by Uhde is explicitly
subject to the approval of Uhde’s Board of Directors. The Parties understand that, for
design-build projects, Myriant envisions using a traditional project finance structure
requiring process and performance guarantees with corresponding liquidated damage provisions
as noted in Item C.3 hereinabove.
	 
	D.	 	Miscellaneous
	 
	D.1 	 	Effective Date
	 
	 	 	This Agreement shall become effective upon execution by the last Party needing to sign
this Agreement.
	 
	D.2 	 	Representation
	 
	 	 	No Party shall have the right or obligation to represent the other
Party or to enter into any obligation of whatever kind for the other
Party. The Parties are independent contractors and nothing in this
Agreement shall be deemed to constitute, create, give effect to or
otherwise recognize a joint venture, partnership, or formal business
entity of any kind and the rights and obligations of the Parties shall
be limited to those expressly set forth herein.

 

			
	***	 	Confidential Treatment Requested

16

 

	D.3 	 	Confidentiality Agreement
	 
	 	 	The Parties shall treat all information exchanged under this Agreement as confidential
information in accordance with the Confidentiality Agreement signed between the Parties on
14 August 2009.
	 
	 	 	Neither Party shall publicly announce or disclose the existence of this Agreement or its
terms and conditions, or advertise or release any publicity regarding this association or
the Project without the prior consent of the other Party, such consent which shall not be
unreasonably withheld or delayed.
	 
	D.4 	 	Term
	 
	 	 	The Agreement shall be valid for a period of seven (7) years from the time stated in Item
D.1 of this Agreement (the “Term”) and shall, in consideration of any necessary
amendments according to Item C.6, continue thereafter if mutually extended by the Parties.
	 
	D.4.1 	 	Termination of Agreement
	 
	 	 	The Parties may elect at any time to mutually terminate this
Agreement at any time prior to the Term hereof. A Party that does
not elect to renew this Agreement shall notify the other of its
intent not to renew this Agreement before the expiry of the Term by
providing the other Party 180 days prior written notice to the other
Party of its intention not to renew.
	 
	D.4.2 	 	Termination with Immediate Effect
	 
	 	 	Either Party may terminate this Agreement — unless otherwise agreed upon between the
Parties — with immediate effect, if

	 	a)	 	insolvency, bankruptcy, liquidation, receivership or dissolution of the
other Party occurs; or
	 
	 	b)	 	either the Parties hereunder or UCA and Myriant, under the terms of the
U.S. Alliance Agreement, do not (i) sign and make effective an EPC or an EP
(depending on the conditions as mentioned in C.3) contract for a Plant with either
Myriant or a third party and have said Plant under constructing and (ii) have
[...***...] under construction within [...***...] after signing this Agreement and at
least [...***...] every [...***...] thereafter; for sake of clarity, the construction
of a [...***...] shall be considered sufficient to fulfil such minimum requirements
(while it is understood that Uhde shall discuss and negotiate with its Affiliate,
UCA, to have the U.S. Alliance Agreement between UCA and Myriant extended
coterminously with this Agreement with the aim that the U.S. Alliance Agreement shall
remain in effect as long as this Agreement between Uhde and Myriant remains valid),
or

 

			
	***	 	Confidential Treatment Requested

17

 

	 	c)	 	the other Party commits a material breach of any of its obligations under
the Agreement, which is not cured after notice, and a reasonable opportunity to cure
such breach.

	 	 	Except in the case of material breach, if one or more Projects have been identified, or
joint proposals have been submitted, by Myriant with Uhde as EPC contractor and/or are
under consideration of an end customer, at the end of the Term, this Agreement shall
continue in force with respect to such Project(s) or proposal(s) until terminated pursuant
to mutual agreement.
	 
	D.5 	 	Cooperation in the light of Antitrust Laws
	 
	 	 	Unless the Agreement is terminated in accordance with D.4.1 or D.4.2, the Parties shall
examine the Term and exclusivity provisions of Part A.1.1 and C.5 of this Agreement no
later than the sixth anniversary of the Effective Date in light of the then applicable
antitrust legislation. If required, the Parties shall make necessary revisions to the Term
and/or exclusivity provisions provided for in this Agreement.
	 
	D.6 	 	Waiver of Terms
	 
	 	 	This Agreement will not be modified except by an instrument in writing signed by or on
behalf of each Party. The failure of either Party to insist, in any one or more instances,
upon the performance of any of the terms, covenants or conditions of this Agreement or to
exercise any right hereunder, will not be construed as a waiver or relinquishment of the
future performance of any such terms, covenants or conditions or the future exercise of
such right, but the obligation of the other Party with respect to such future performance
will continue to be in full force and effect.
	 
	D.7 	 	Entire Agreement, Execution Costs, No Assignment
	 
	 	 	This Agreement and the Confidentiality Agreement referred to hereinafter in Item D.3
contains the entire agreement between the Parties with respect to the subject matter of
this Agreement and the transactions contemplated herein and it supersedes all prior
collateral communications, reports and understandings between the Parties with respect
thereto, including the Cooperation Agreement referred to hereinabove. It is understood
that this Agreement does not affect any other agreements between the Parties except those
specified herein. The Parties recognize and acknowledge that UCA and Myriant are
concurrently entering into a parallel agreement with similar terms and conditions for the
United States.
	 
	 	 	Each of the Parties shall bear its respective fees, costs, and expenses in connection with
the execution of this Agreement. Neither Party may assign this Agreement, in whole or in
part, or any rights hereunder without the prior written consent of the other Party, such
consent which will not be unreasonably withheld or delayed.

 

			
	***	 	Confidential Treatment Requested

18

 

	D.8 	 	Liability/ Indemnity
	 
	 	 	DURING THE EXECUTION OF THE RESEARCH AND DEVELOPMENT PROCESS; EACH PARTY SHALL USE ITS
CUSTOMARY CARE AND DILIGENCE IN ACCORDANCE WITH THE ACKNOWLEDGED SCIENTIFIC STANDARDS AND
TECHNOLOGY.
	 
	 	 	NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR THE SUITABILITY, CORRECTNESS,
COMPLETENESS OR OTHER QUALITIES OF ANY OF THEIR RESEARCH AND DEVELOPMENT RESULTS AND
INFORMATION PROVIDED TO EACH OTHER UNDER THIS AGREEMENT. THE PARTIES SHALL EXPLICITLY NOT
BE LIABLE TO EACH OTHER FOR THE FAILURE TO ACHIEVE OF ANY OF THE GOALS OF THE ALLIANCE.
	 
	 	 	NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY BY WAY OF INDEMNITY OR BY REASONS OF TORT
(INCLUDING BUT NOT LIMITED TO NEGLIGENCE) OR OTHERWISE FOR ANY LOSS OF PROFIT, LOSS OF
USE, LOSS OF PRODUCTION, LOSS OF CONTRACT OR ANY FINANCIAL OR ECONOMIC LOSS OR FOR ANY
INDIRECT OR CONSEQUENTIAL DAMAGE OF WHATEVER CAUSE.
	 
	 	 	THE PARTIES’ RIGHTS AND REMEDIES AS STATED HEREIN ARE EXCLUSIVE AND IN LIEU OF ALL OTHER
REMEDIES WHETHER STATUTORY, EXPRESS OR IMPLIED AND ARE THE SOLE REMEDIES OF A PARTY FOR
THE FAILURE BY THE OTHER PARTY TO COMPLY WITH ITS OBLIGATIONS.
	 
	D.9 	 	Governing Law/Mediation/Arbitration
	 
	 	 	This Agreement shall be governed by and construed in accordance with the Substantive Laws
of Switzerland, without giving effect to their conflicts of law principles.
	 
	 	 	For any disputes between the Parties relating to Intellectual Property matters as provided
herein or that may otherwise arise between the Parties under this Agreement or in the
Alliance, the Parties may, in the first instance, without prejudice to any other
proceedings, seek to settle any dispute arising out
of or in connection with the present contract in accordance with the International Chamber
of Commerce (the “ICC”) ADR Rules (the “ICC ADR Rules”). The Parties shall jointly
appoint a sole intellectual property mediator who is a nationally recognized expert in
intellectual property matters to adjudicate such disputes. Failing the joint appointment,
the mediator shall be chosen by the ICC. Each Party may be represented by counsel at the
mediation, but each Party must attend through an officer having authority to agree to a
settlement at the mediation. The mediation session shall occur in Zurich, Switzerland, and
shall extend no longer than a single day. Statements or offers made at the mediation
session shall not be admissible in any later arbitration hearing. Each Party shall bear
its own fees and expenses, including payments to its own chosen experts, and an equal
share of the expenses and fees of the mediator and the ICC. The Parties, their

 

			
	***	 	Confidential Treatment Requested

19

 

	 	 	representatives, other participants and the mediator shall hold the existence, content and
result of the mediation in confidence.
	 
	 	 	Any disputes arising out of or in connection with this Agreement shall exclusively and
finally be settled under the Rules of Arbitration (the “ICC Rules”) of the
International Chamber of Commerce (the “ICC”) The arbitral tribunal determining
any dispute shall be comprised of three arbitrators. Each Party to a dispute shall
designate one arbitrator. If a Party fails to designate an arbitrator within a reasonable
period, the ICC shall designate an arbitrator for such Party. The two arbitrators
designated by the Parties to a dispute (or, if applicable, the ICC) shall designate a
third arbitrator. In the event that the two arbitrators designated by the Parties to a
dispute (or, if applicable, the ICC) are unable to agree upon a third arbitrator within a
reasonable period, the third arbitrator shall be selected in accordance with the ICC Rules
by the ICC. The language of the arbitration shall be in English, and the place of the
arbitration of any dispute shall be held in Zurich, Switzerland or any other venue as
agreed upon by the Parties to such a dispute. If neither the Parties nor the arbitral
tribunal can agree upon procedures, the arbitration shall be conducted in accordance with
the ICC’s procedures. The hearings and taking of evidence of any dispute may be conducted
at any locations that will, in the judgment of the arbitral tribunal, result in a speedy,
efficient and just resolution of such dispute. The Parties to any dispute shall use their
reasonable best efforts to cooperate with each other and the arbitral tribunal in order to
obtain a resolution as quickly as possible, including by adopting the ICC’s “fast-track”
procedure (as provided for in Article 32(1) of the ICC Rules) if appropriate.
	 
	 	 	Notwithstanding the above, each Party acknowledges that its breach of the Agreement may
cause irreparable damage to the other Party and hereby agrees that without prejudice to
the before mentioned the other Party shall be entitled to seek injunctive relief under
this Agreement for such breach.
	 
	D.10 	 	Amendments
	 
	 	 	This Agreement may not be changed or amended orally, but only in writing signed by the
Parties hereto. The writing must refer to this Agreement and must expressly state that it
is an amendment hereof.
	 
	D.11 	 	Severability
	 
	 	 	The circumstance that any provision or part of it of this Agreement
is held to be void, illegal, unenforceable or contrary to law or
public policy shall not affect the validity of the remaining
provision(s) of this Agreement. The invalid, illegal or
unenforceable provision or part of it will be replaced by an
admissible one, aiming at the same economic and legal results.
	 
	D.12 	 	Force Majeure
	 
	 	 	No Party shall be liable, in respect to any delay in completion     of
work hereunder or of the non-performance of any term or condition
of this Alliance directly or indirectly resulting from delays by
Acts of God; acts of the public enemy; strikes; lockouts; epidemic
and riots; power failure; water shortage or

 

			
	***	 	Confidential Treatment Requested

20

 

	 	 	adverse weather conditions; or other causes beyond the control of the Parties. In the event
of any of the foregoing, the time for performance shall be equitably and immediately
adjusted, and in no event shall any Party be liable for any consequential or incidental
damages from its performance or non-performance of any term or condition of this Alliance.
The Parties shall resume the completion of work under this Alliance as soon as possible
subsequent to any delay due to force majeure.
	 
	D.13 	 	Further Assurances
	 
	 	 	The Parties agree and acknowledge that this Agreement grants certain rights
and responsibilities to each other and that it also provides certain
“framework” arrangements of a prospective nature between the Parties. In
that regard, the Parties may elect to enter into such other agreements as may
be necessary to reflect the intent of the Parties on a going—forward basis.

	 	 	 	 	 	 	 	 	 

	Myriant Technologies LLC	 	 	 	Uhde GmbH
	 
	 	 	 	 	 	 	 	 
	Place, Date: Quincy, 6 October 2009	 	 	 	Place, Date: Dortmund, 6 October 2009
	 
	 	 	 	 	 	 	 	 
	Signature:

	 	/s/ Samuel G. McConnell
	 	 	 	Signature:
	 	/s/ Joachim Schultze
	 

	 	 
	 	 	 	 	 	 
	Name:        Samuel G. McConnell	 	 	 	Name:        Joachim Schultze
	 
	 	 	 	 	 	 	 	 
	Position: Senior Vice President	 	 	 	Position: Head of Uhde Biotechnology

 

			
	***	 	Confidential Treatment Requested

21

 

Annex 1-Definitions

	 	 	 

	Affiliate(s)

	 	An Affiliate of a Party is a person or entity that directly, or indirectly through
one or more intermediaries, controls, or is controlled by, or is under common control
with, such Party.
	 
	 	 
	Agreement

	 	means this Global Alliance Agreement in its version as signed by both Parties and of
which each Party shall hold one original copy.
	 
	 	 
	Alliance

	 	means the relationship between the Parties contemplated by this Agreement.
	 
	 	 
	EP

	 	means the engineering and procurement functions for the Plants (located outside of
the United States).
	 
	 	 
	EPC

	 	means the engineering, procurement and construction functions for the Plants (located
outside of the United States).
	 
	 	 
	Field

	 	means the field of Succinic Acid.
	 
	 	 
	Intellectual Property Rights

	 	means any and all Intellectual Property Rights in, to, or
arising out of any (i) Patents; (ii) trade secrets; (iii) know-how; (iv) copyrights,
copyright registrations, or any national or regional application therefor, in any
territory, or any other right corresponding thereto throughout the world; or (v) any other
intellectual property or proprietary right anywhere in the world.
	 
	 	 
	Joint Working Results

	 	means (i) improvements to the Myriant Process made by Uhde or
jointly by Uhde and Myriant, (ii) improvements to the Uhde Process made by Myriant or
jointly by Uhde and Myriant, (iii) new processes jointly developed by the two Parties, or
(iv) new processes developed solely or substantially by one of the Parties with reference
to the other Party’s intellectual property, as such improvements or new processes are
developed within the scope of the collaboration as defined herein, together and/or
singularly, as the context may indicate.
	 
	 	 
	Myriant

	 	means Myriant Technologies LLC, a limited liability company duly organised under the
laws of Delaware with its principal office at 1 Pinehill Drive, Batterymarch Park II,
Suite 301, Quincy, MA 02169, USA.
	 
	 	 
	Myriant Improvement

	 	means any improvement to the Myriant Process solely developed by Myriant
without reference to any Uhde or Uhde intellectual property.

 

			
	***	 	Confidential Treatment Requested

22

 

	 	 	 

	Myriant Process

	 	means a proprietary fermentation technology developed by Myriant [...***...].
	 
	 	 
	Patent

	 	means any and all rights under any of the following, whether existing now or in the
future: (i) all national, regional and international patents and patent applications,
including provisional patent applications, utility model, design registration, certificate
of invention, patent of addition or substitution, or other governmental grant for the
protection of inventions or industrial designs anywhere in the world, including any
reissue, renewal, re-examination or extension thereof; and (ii) any application for any of
the foregoing, including any international, provisional, divisional, continuation,
continuation-in-part, or continued prosecution application.
	 
	 	 
	Pilot Plant

	 	means the Fermic Sa de CV’s tolling facility in Mexico City, Mexico configured
and contracted by Myriant for the production of Succinic Acid at a semi-industrial scale.
	 
	 	 
	Plant(s)

	 	means commercial scale Succinic Acid production facility(ies) located outside the
United States utilizing the Processes.
	 
	 	 
	Prior IP Record

	 	means any Patent application; document substantiating the existence of a
trade secret, proprietary technology or know-how; copyrighted work; copyright
registration; engineering lab book, record or drawing, or any national or regional
application therefor.
	 
	 	 
	Project

	 	means that series of activities and tasks in support of the financing, siting, design,
engineering, construction procurement and/or operation of commercial scale Plants located
outside of the United States utilizing the Processes.
	 
	 	 
	Processes

	 	means the Myriant Process together with the Uhde Process when the context so
indicates.
	 
	 	 
	Steering Committee

	 	means the Alliance steering committee comprised of four (4) members with
equal representation by Myriant and Uhde.
	 
	 	 
	UCA

	 	means Uhde Corporation of America, a company duly organised under the laws of
Delaware with its principal office at 1370 Washington Pike, Bridgeville, PA 15017, USA and
an Affiliate of Uhde (defined hereunder).
	 
	 	 
	UCA-Myriant 

Demonstration Plant

	 	means the contemplated Succinic Acid production facility
with an annual output of 30 million pounds to be located in the United
States.

 

			
	***	 	Confidential Treatment Requested

23

 

	 	 	 

	Uhde

	 	means Uhde GmbH, a company duly organised under the laws of the Federal Republic of
Germany with its principal office at Friedrich-Uhde-Str. 15, 44141 Dortmund, Germany.
	 
	 	 
	Uhde Improvement

	 	means any improvement to the Uhde Process solely developed by Uhde
without reference to any Myriant intellectual property.
	 
	 	 
	Uhde Process

	 	means a proprietary separation technology developed by Uhde [...***...]
	 
	 	 
	Joint Working Results

	 	means (i) improvements to the Myriant Process made by Uhde or by
Myriant and Uhde jointly, (ii) improvements to the Uhde Process made by Myriant or by
Myriant and Uhde jointly, (iii) new processes jointly developed by the two Parties, or
(iv) new processes developed solely or substantially by one of the Parties but with
reference to the other Party’s intellectual property, as such improvements or new
processes are developed within the scope of the collaboration as defined herein, together
and/or singularly, as the context may indicate.

 

			
	***	 	Confidential Treatment Requested

24

 

	 	 	EXHIBIT A — Uhde Process License Fee Structure

License Fee in EUR:

	 	•	 	for capacities below [...***...] MT/year: [...***...]
	 
	 	•	 	for capacities between [...***...] and [...***...] MT/year:

	 	o	 	[...***...]
	 
	 	o	 	[...***...]

	 	•	 	for capacities above [...***...] MT/year: to be discussed.

 

			
	***	 	Confidential Treatment Requested

25

 

EXHIBIT B — Engineering and Plant Proposal Fees

	 	 	For Engineering Services including Plant Proposal services provided by Uhde under this
Agreement, Myriant shall pay to Uhde the following hourly rates:

	 	a)	 	for home office engineering performed by Uhde through Uhde in Germany:
[...***...];
	 
	 	b)	 	for home office engineering performed by Uhde through Uhde Engineering de
Mexico S.A. de C.V.: [...***...]; and
	 
	 	c)	 	for assignment of personnel out of home office, the Parties shall agree on
daily rates including incidental cost in due course.

	 	 	The rates indicated under a) through c) above are based on 40 working hours/week (Mon-Fri)
and shall be valid until 30.09.2010. Thereafter, the rates shall be escalated on the first
date of each subsequent year in accordance with the increase of salaries and incidental
salary expenses as substantiated by Uhde.
	 
	 	 	The above rates may differentiate between different categories and different Uhde offices.
	 
	 	 	The Parties shall mutually agree at agreed intervals on which rates shall be applied to
which work packages.
	 
	 	 	Additional cost, e.g. travel and accommodation cost in case of business trips, etc., shall
be reimbursed in addition to the above rates.
	 
	 	 	The above mentioned rates shall be invoiced by Uhde on a monthly basis and shall be
payable within 30 days after receipt of invoice.
	 
	 	 	Compensation for Supplies
	 
	 	 	[...***...] shall be mutually agreed prior to the start of engineering of any
Plant (located outside the United States) constructed by the Parties pursuant to this
Agreement.

 

			
	***	 	Confidential Treatment Requested

26

 

EXHIBIT C — [...***...]

[...***...]

 

			
	***	 	Confidential Treatment Requested

27exv10w4

Exhibit 10.4

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4)

and 203.406

SUPPLY CONTRACT

     THIS SUPPLY CONTRACT (the “Contract”), is executed as of this 15th day of
June, 2010, by and between Myriant Technologies LLC, a Delaware limited liability corporation
(herein, together with its successors and assigns, “Seller”), and Johann Haltermann Ltd., a
Texas Limited Partnership (herein, together with its successors and permitted assigns,
“Buyer”).

     WHEREAS, Seller is building a commercial manufacturing facility to produce Succinic Acid that
is expected to commence production in [...***...], and will also produce Succinic Acid in a third
party facility that is expected to commence production in [...***...], and desires to sell a
certain amount of its annual production of Succinic Acid (the “Succinic Acid”); and

     WHEREAS, Buyer desires to purchase from Seller, and Seller desires to supply Buyer with all of
Buyer’s needs and requirements for Succinic Acid pursuant to the terms and conditions set forth in
this Contract.

     NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein,
Seller and Buyer hereby agree as follows:

1. Term. The term of this Contract shall begin on the earlier of (i) the date on which the
Seller has the capability to produce Succinic Acid at an annualized [...***...] of [...***...]; or
(ii) the [...***...] of commercial operations of the Seller’s Succinic Acid manufacturing plant
located in [...***...] (such date referred to herein as the “Trigger Date”). The initial
term shall commence on the Trigger Date and continue for five (5) years thereafter. The Contract
shall continue thereafter for successive terms of one calendar year each, unless terminated by
Buyer or Seller on not less than six (6) months prior written notice to the other party or unless
sooner terminated as provided herein. Seller shall provide Buyer with advance written notice of
the anticipated Trigger Date (the “Trigger Date Notice”), which shall in no event be prior
to thirty (30) days prior to the actual Trigger Date.

2. Quantity. Buyer hereby agrees to purchase one hundred percent (100%) of its requirements
of Succinic Acid from Seller, and Seller hereby agrees to supply Buyer with not more than twenty
(20) million pounds of Succinic Acid annually

3. Specification. The Succinic Acid Specification will be defined in a mutually agreeable
Exhibit A, to be determined prior to the Trigger Date.

4. Price. The price of Succinic Acid sold by Seller to Buyer hereunder shall be determined
in accordance with a mutually agreed formula (“Exhibit B: Pricing Formula”) which shall be
based upon and indexed to certain agreed upon commodity prices and shall be [...***...] according
to the provisions of this Section 3. Within five (5) days of providing the Trigger Date Notice,
Buyer and Seller shall meet to determine the Pricing Formula for the [...***...] and any partial
period
beginning on the Trigger Date before the commencement of the first full [...***...]. As used
herein, [...***...] beginning on the 5th calendar day of the month.

 

			
	***	 	Confidential Treatment Requested

 

 

This initial price of the Succinic Acid as determined by the Pricing Formula shall remain firm
until the beginning of the second full [...***...]. Prior to the beginning of the next
[...***...], Seller and Buyer shall negotiate the Pricing Formula for the Succinic Acid for that
[...***...]. Each negotiated price for Succinic Acid shall be effective for one [...***...]. Until
Seller and Buyer agree on a price for the next [...***...], the purchase price then existing will
remain in effect.

5. Forecasts. At least thirty (30) days prior to the first shipment of Succinic Acid by
Seller to Buyer under this Contract, Buyer shall provide Seller with a written forecast (the
“Initial Forecast”) of the amount of Succinic Acid that Buyer intends to purchase in the
first [...***...] following the effective date of this Contract, and a rolling annual forecast of
the amount of succinic acid Buyer intends to buy over the next twelve month period. Thereafter, on
or before the fifth day of each [...***...], Buyer shall submit to Seller a written forecast of the
quantity of Succinic Acid (the “Forecast”) that Buyer intends to purchase during that
[...***...]. Such Forecasts shall be non-binding upon either party.

6. Sale and Purchase. Seller agrees to sell to Buyer, and Buyer agrees to purchase from
Seller such quantities of Succinic Acid as specified in purchase orders which are issued by Buyer
to Seller from time to time during the Term of this Contract. Seller cannot guarantee the ability
to supply Product to Buyer if the volume requested by purchase order exceeds [...***...] of the
[...***...] Forecast Volume. The purchase price and the other terms and conditions of such sales
shall be as specified in said purchase orders and order acknowledgments containing Seller’s
Standard Terms and Conditions (a copy of which is set forth on Exhibit C attached hereto);
provided, however, in the event of any conflict or inconsistency between or among the terms of this
Contract, the purchase orders, and the order acknowledgments containing Seller’s Standard Terms and
Conditions, the conflict or inconsistency shall be resolved by giving precedence in the following
order: (i) this Contract, (ii) the order acknowledgements containing Seller’s Standard Terms and
Conditions, and (iii) the purchase orders.

7. Invoicing and Payments. Buyer acknowledges that it shall make payments on a monthly
basis, without any right of offset. Seller shall invoice all shipments in a single invoice monthly.

8. [...***...]. If after [...***...] following the effective date of this Contract, Buyer
receives a written offer from a reputable [...***...] not controlled by or controlling Buyer, to
[...***...] of the Succinic Acid [...***...] hereunder which are [...***...], for [...***...] and
[...***...], at [...***...], and Buyer determines in its sole discretion that [...***...], then
upon Buyer’s written notice providing all the terms and conditions, including [...***...], Seller
may by written notice within [...***...] of receipt of Buyer’s notice: (a) [...***...] and amend
this Contract accordingly; or (b) [...***...], and amend this Contract accordingly. If Seller has
not exercised its options above within said [...***...], then Buyer may either (i) elect option (b)
on behalf of Seller by written notice to Seller within [...***...] after the expiration of such
period for Seller’s election, or (ii) cancel this Contract upon [...***...] prior written notice.

9. Title and Risk of Loss and Freight Terms. Title and Risk of Loss with respect to the
Succinic Acid sold hereunder shall transfer from Seller to Buyer at the time the Succinic Acid is
placed in the possession of the Buyer. At the meeting at which Buyer and Seller are determine the
Pricing Formula as provided in Section 3 hereof, the Buyer and Seller shall mutually agree as to
the freight terms for shipment of the Succinic Acid to the Buyer.

 

			
	***	 	Confidential Treatment Requested

 

 

10. Warranties. Seller warrants that the Succinic Acid delivered hereunder shall meet
Seller’s standard quality or such other specifications as have been expressly attached hereto and
made part of this Contract. SELLER MAKES NO WARRANTY AS TO THE FITNESS OF THE SUCCINIC ACID FOR ANY
PARTICULAR PURPOSE OR THE RESULTS TO BE OBTAINED FROM ITS USE BY BUYER EITHER ALONE OR IN
COMBINATION WITH OTHER SUBSTANCES. SELLER MAKES NO OTHER REPRESENTATIONS OR WARRANTIES OF ANY KIND,
EXPRESS OR IMPLIED, WITH RESPECT TO THE SUCCINIC ACID.

11. Limitation of Liability. All claims for damages shall be deemed waived unless Buyer
submits such claims to Seller in writing within ninety (90) days from the shipment of Succinic
Acid. Seller’s liability for any claim shall be limited to the purchase price of the Succinic Acid
in respect of which such damages are claimed. In no event shall Seller be liable for special,
indirect or consequential damages.

12. Taxes. Buyer shall reimburse Seller for all taxes (excluding margin taxes, franchise
taxes and taxes upon Sellers’s income or property), excise or other charges that Seller may be
required to pay to any government (national, state, provincial or local) upon, or measured by, the
sale, production, transportation or use of any Succinic Acid sold hereunder.

13. Force Majeure. Neither party shall be liable for its failure to perform hereunder if
said performance is made impracticable due to any circumstances beyond the reasonable control of
the party affected, including, but not limited to, acts of God, fires, floods, wars, sabotage, acts
of government or other legal authority, terrorism, civil unrest, pandemic flu, accidents, labor
disputes or shortages, plant shutdown, shortage of materials, equipment failure, voluntary or
involuntary compliance with any law, order, rule or regulation of government agency or authority,
or inability to obtain material (including power and fuel), equipment or transportation. The
affected party may omit purchases or deliveries during the period of continuance of such
circumstances and the Contract quantity shall be reduced by the quantities omitted. During any
period when Seller shall be unable to supply the total demands for the Succinic Acid provided for
in this Contract, whether caused by the circumstances specified above or otherwise, Seller may
allocate any available Succinic Acid among all buyers on such basis as it may deem fair and
practical.

14. Separate Transactions; Default. Each shipment shall constitute a separate and
independent transaction and Buyer or Seller may recover for such shipment without reference to any
other. If Buyer or Seller is in default with respect to any of the terms and conditions of this
Contract, the other party may, at its option, defer further shipments hereunder until such default
be remedied (in which event the non-defaulting party may elect to extend the Contract period for a
time equal to that for which shipments were so deferred), or, in addition to any other legal
remedy, the non-defaulting party may decline further performance of this Contract.

15. Entire Agreement. This Contract constitutes the entire agreement between the parties
with respect to the subject matter hereof and there are no understandings, representations or
warranties of any kind, express or implied, not expressly set forth herein. No modification of this
Contract shall be of any force or effect unless such modification is in writing and signed by the
party to be bound
thereby; and no modifications shall be effected by the acknowledgment or acceptance of purchase
order forms containing terms or conditions at variance with those set forth herein.

 

			
	***	 	Confidential Treatment Requested

 

 

16. Successors and Assigns. This Contract shall the binding upon and inure to the benefit
of the respective successors and assigns of each of the parties hereto, but shall not be assigned
by Buyer without the prior written consent of Seller, which consent shall not be unreasonably
withheld.

17. No Waiver. Seller’s waiver of any breach, or failure to enforce any of the terms and
conditions of this Contract, at any time, shall not in any way affect, limit or waive Seller’s
right thereafter to enforce and compel strict compliance with every term and condition hereof.

18. Governing Law; Jurisdiction. This Contract shall be governed by the laws of the State
of Delaware and the courts of the State of Delaware shall have exclusive jurisdiction to resolve
any dispute arising under this contract.

19. Counterparts. This Contract may be executed in counterparts, each of which shall be
deemed an original, but all of which shall constitute one document.

20. Independent Contractors. For the purposes of this Contract, Buyer and Seller shall be,
and shall be deemed to be, independent contractors and not agents or employees of the other party.
No party shall have the authority to make any statements, representations, or commitments of any
kind, or to take any action which shall be binding on the other party, except as may be explicitly
provided for herein or authorized in writing.

21. Notice. Any notice, demand, or communication required or permitted to be given by any
provision of this Contract shall be in writing and deemed to have been sufficiently given or served
for all purposes by (i) actual delivery of the notice; (ii) the mailing of the notice in the U.S.
mail, certified mail, return receipt request; or (iii)sending by nationally recognized, overnight
delivery service to the other party as follows:

If to the Seller:

Myriant Technologies LLC

Two Batterymarch Park

Quincy, MA 02169-4801

Attn: Michael Mang

If to the Buyer:

16717 Jacintoport Boulevard,

Houston, TX 77015

Attn: Jeff Weeks

[Signature Pages Follow]

 

			
	***	 	Confidential Treatment Requested

 

 

IN WITNESS WHEREOF, the Buyer and Seller hereto have duly executed and delivered this Contract as
of the date and year first above mentioned.

	 	 	 	 	 
	 	Myriant Technologies LLC

 	 
	 	By:  	/s/ Alif Saleh
 	 
	 	Its: Senior Business Director 	 
	 	 	 	 
	 

[Signature Page to Supply Contract]

 

			
	***	 	Confidential Treatment Requested

 

 

	 	 	 	 	 
	 	Johann Haltermann Ltd.

 	 
	 	By:  	/s/ Jeff Weeks
 	 
	 	Its: Commercial Manager 	 
	 	 	 	 
	 

[Signature Page to Supply Contract]

 

			
	***	 	Confidential Treatment Requested

 

 

MYRIANT TECHNOLOGIES LLC

TERMS AND CONDITIONS OF SALE OF PRODUCTS

Effective June 15, 2010

1. Contract Formation and Acceptance. In the absence of a written agreement to the contrary
executed by Myriant Technologies LLC or one of its affiliates or subsidiaries (“Myriant”),
these terms and conditions (the “Terms”) shall apply to every sale of goods
(“Products”) between Myriant and the party purchasing the Products (“Buyer”) and
shall survive any termination (by mutual agreement or otherwise) of these Terms. A quotation by
Myriant does not constitute an offer and Myriant reserves the right to withdraw or revise any
quotation prior to time of its acceptance of an order from Buyer. The contract shall be formed at
the time when Buyer’s order is confirmed in writing by Myriant or delivery of the Products is made
by Myriant and Myriant’s acceptance of the Buyer’s purchase order is expressly made conditional on
Buyer’s assent to these Terms.

2. Price and Taxes. The price for Products shall be the price quoted by Myriant to Buyer or, when
no price is quoted, the Myriant’s list price at date of delivery, unless otherwise agreed in
writing by the parties. Prices are subject to change at anytime without advance notification,
unless there is a binding contract between Myriant and Buyer. All prices quoted shall be exclusive
of sales tax or other applicable taxes, tariffs, duties or charges which are payable by Buyer.
Myriant may increase or decrease its prices at any time. New prices shall apply to Products not yet
delivered provided Myriant has notified Buyer in writing, who shall have ten (10) days prior to
delivery to cancel further deliveries at such increased price by sending a written cancellation to
Myriant without being entitled to any damages from Myriant. Unless otherwise specifically agreed in
writing, Buyer shall be responsible for payment of all freight charges and any freight charges
incurred by Myriant, including any increases in charges, shall be for the account of Buyer and
shall apply to any balances unshipped or undelivered from warehouse at time the freight increase
becomes effective. Any tax, tariff, duty or charge which Myriant may be required to pay or collect,
now or hereafter imposed by any governmental authority or agency, foreign or domestic, with respect
to the sale, purchase, production, processing, storage, delivery, transportation, use, or
consumption of any of the products or services covered hereby, including all taxes upon or measured
by receipts from sales or services, shall be for the account of Buyer, and any such charges may be
added by Myriant as a separate item to Myriant’s invoices.

3. Payment. All invoices are payable in full within thirty (30) days of date of the invoice and
payable in United States funds (unless a different currency is specified in the invoice), free of
exchange collection, or other charges. If Buyer fails to pay any invoice in full when due, or if
Myriant shall have any doubt at any time as to Buyer’s financial responsibility or capability,
Myriant may suspend production and/or decline to make shipment or delivery. Myriant reserves the
right to request payment or other form of security prior to delivery. Upon any default in payment,
Buyer shall pay Myriant interest on the unpaid balance at the lesser of 12% interest per annum or
the maximum interest rate permitted by law and all costs of collection, including attorneys’ fees
and expenses. Myriant shall have, and Buyer hereby grants to Myriant, a purchase money security
interest in all products purchased by Buyer and any product proceeds to secure payment of the
purchase price and all other amounts due Myriant, and Myriant shall retain all rights and remedies
of a secured party under the Uniform Commercial Code (or under comparable laws outside the United
States) including the right to repossess or require Buyer return products for which Myriant does
not have payment. Upon the request of Myriant, Buyer shall take such action as Myriant may deem
necessary or appropriate to protect, maintain, record or otherwise assure to Myriant the foregoing
security interest.

4. Delivery. Title to the Products and risk of loss of the Products shall pass to Buyer upon
delivery to a carrier or to Buyer truck (F.O.B. shipping point). If Buyer fails to fulfill terms
of purchase or payment under these Terms, Myriant may defer further shipments without notice until
such default is made good, or may treat such default as a final refusal by Buyer to accept further
shipments hereunder. Each delivery under these Terms shall be deemed to be a separate transaction,
and the cancellation or rejection of any delivery shall not affect the rights and obligations of
the parties under the agreement as a whole. Unless otherwise specifically provided herein, delivery
shall be F.O.B. point of shipment, all risk of loss shall pass to Buyer upon delivery to carrier or
into Buyer’s transports, and Buyer shall be responsible for obtaining and paying for insurance
(including war risk insurance) if desired. Unless otherwise agreed in writing, Products shall be
shipped in the manner and route of transportation Myriant decides. Dates proposed by Myriant for
delivery are approximate and Myriant shall not be liable for any delay in delivery of Products.
Time for delivery shall not be of the essence.

5. Intellectual Property.

(a) If the Products themselves, as and when sold at Myriant’s product specifications, become the
subject of a patent infringement claim, Myriant may, at its sole option and expense, either replace
or modify the Products, provide for the return of Products and refund the purchase price paid by
Buyer, or procure for Buyer the right to continue to use such Products. The foregoing states
Buyer’s sole remedy and Myriant’s entire obligation and liability with respect to any and all
intellectual property claims.

 

			
	***	 	Confidential Treatment Requested

 

 

(b) Buyer shall defend, indemnify and hold harmless Myriant from and against all loss, costs,
expenses, damages and liability of any kind arising out of any claims of infringement or alleged
infringement of any patent or other intellectual property right with respect to (i) the use of
Products in any application by Buyer or its affiliates, contract manufacturers or customers,
including but not limited to the use of Products alone or in combination with other substances or
components; (ii) any modification to the Products by Buyer or its affiliates, contract
manufacturers or customers; or (iii) Products furnished, or methods used, by Myriant in accordance
with the specifications or instructions furnished by or expressly or implicitly prescribed by
Buyer.

(c) Except as may be contained in a separate trademark license, the sale of Products (even if
accompanied by documents using a trademark or trade name of Myriant) does not convey a license,
express or implied, to use any trademark or trade name of Myriant, and Buyer shall not use any
trademark or trade name of Myriant in the conduct of its business without Myriant’s prior written
consent.

6. Force Majeure

Myriant shall not be liable for any failure to perform or delay in performance due to fire;
explosion; accident, theft, flood; accident; Acts of God; pandemics, labor difficulties; shortage
or unavailability on reasonable commercial terms of utility, facility, raw materials or labor;
delay in or unavailability on reasonable commercial terms of transportation; breakdown of equipment
or machinery; compliance with or other action taken to comply with any law or regulation; acts of
war or terrorism; restraints or requirements of any government or governmental authority or their
agents; or any other causes or contingencies, whether similar or dissimilar, beyond Myriant’s
reasonable control. In the case of such an event, Myriant may, in its sole discretion, cancel,
reduce or modify its deliveries to Buyer without liability for any damages whatsoever.

7. Warranty; Claims; and Limitation of Liability. Buyer agrees that the following terms and
conditions have applied and shall apply to all Products sold or agreed to be sold to Buyer by
Myriant and shall not be supplemented, modified or amended unless agreed to in a writing signed by
an officer of Myriant.

(a) Limited Warranty. The Myriant warrants all grades of Products to be supplied by Myriant to
Buyer shall meet the product specifications for such grade set by Myriant from time to time, or as
modified, in writing, by the mutual agreement of both parties. Claims in respect of any products at
any time sold or agreed to be sold by Myriant, whether in contract, tort or otherwise (including
negligence or misrepresentation), including claims on account of weight, quality, loss or damage to
said products, are waived by Buyer unless made in writing within 30 days after arrival thereof at
destination. In case of a timely claim concerning quality, Buyer shall promptly furnish to Myriant
appropriate samples of nonconforming Product for testing and analysis.

(b) Disclaimer of Other Warranties, Representations and Conditions. THE LIMITED WARRANTY ABOVE SETS
FORTH THE SOLE WARRANTY OF MYRIANT WITH RESPECT TO ANY PRODUCTS AT ANY TIME SOLD TO BUYER. ALL
OTHER WARRANTIES AND REPRESENTATIONS AND CONDITIONS OF ANY KIND, WHETHER EXPRESS OR IMPLIED, AND
WHETHER ARISING UNDER STATUTE OR UNDER CONVENTION (INCLUDING THE UNITED NATIONS CONVENTION ON
CONTRACTS FOR THE INTERNATIONAL SALE OF GOODS), ARE HEREBY EXPRESSLY EXCLUDED AND DISCLAIMED,
INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR
NON-INFRINGEMENT OF THIRD PARTY INTELLECTUALLY PARTY RIGHTS. THIS SHALL APPLY WHETHER THE PRODUCTS
ARE USED ALONE OR IN COMBINATION WITH OTHER SUBSTANCES OR MATERIALS, EVEN IF THE PURPOSES OR USES
OF SUCH PRODUCTS ARE KNOWN BY MYRIANT OR IF MYRIANT HAS BEEN INVOLVED IN THE ANALYSIS OF THE
PURPOSES OR USES OF SUCH PRODUCTS OR HAS PROVIDED ANY RECOMMENDATIONS, ASSISTANCE OR INSTRUCTIONS
IN CONNECTION THEREWITH. BUYER ACCEPTS AND ASSUMES ALL RESPONSIBILITY, RISK AND LIABILITY FOR, AND
AGREES TO DEFEND, INDEMNIFY AND HOLD MYRIANT HARMLESS FROM AND AGAINST, ANY CLAIMS OR LIABILITIES
RELATING TO ANY SUCH PRODUCTS OR ANY PRODUCTS MANUFACTURED BY BUYER CONTAINING ANY SUCH PRODUCTS
PROVIDED BY MYRIANT.

(c) Limitation of Remedies. Myriant’s liability, and Buyer’s sole remedy, for any claim in respect
of any products at any time sold or agreed to be sold by Myriant, is limited to, at Myriant’s
option (i) replacing the particular quantity of nonconforming Product or (ii) refunding the
purchase price of the particular quantity of nonconforming product, less the value, if any, to
Buyer of the nonconforming product. IN NO EVENT WILL MYRIANT’S AGGREGATE LIABILITY TO BUYER FOR ALL
DAMAGES ARISING FROM ANY AND ALL CLAIMS RELATED TO THE BREACH OF THESE TERMS, NON-DELIVERY, OR THE
PROVISION OF ANY PRODUCTS, REGARDLESS OF WHETHER THE FORM OF ACTION IS BASED ON CONTRACT, TORT
(INCLUDING NEGLIGENCE), STRICT LIABILITY, STATUTE, OR OTHERWISE, EXCEED THE TOTAL PRICE PAID BY
BUYER TO MYRIANT FOR THE PRODUCTS IN RESPECT OF WHICH DAMAGES ARE CLAIMED. NO CLAIM SHALL BE
ALLOWED FOR PRODUCT THAT HAS BEEN PROCESSED IN ANY MANNER. FAILURE TO GIVE NOTICE OF A CLAIM
WITHIN NINETY (90) DAYS FROM THE DATE OF DELIVERY, OR THE DATE FIXED FOR DELIVERY (IN CASE OF
NON-DELIVERY) SHALL CONSTITUTE A WAIVER BY BUYER OF ALL CLAIMS IN RESPECT OF SUCH PRODUCTS.
PRODUCTS SHALL NOT BE RETURNED TO MYRIANT WITHOUT MYRIANT’S PRIOR WRITTEN PERMISSION. IN ADDITION,
AND TO THE MAXIMUM EXTENT PERMITTED BY LAW, BUYER WAIVES ANY CLAIM TO INDIRECT,

 

			
	***	 	Confidential Treatment Requested

 

 

CONSEQUENTIAL (INCLUDING WITHOUT LIMITATION ANY LOSS OF PROFITS EVEN IF ADVISED OF THE POSSIBILITY
THEREOF), PUNITIVE, EXEMPLARY OR MULTIPLIED DAMAGES ARISING OUT OF OR RELATING TO THESE TERMS OR
THE PROVISION OF ANY PRODUCT.

8. Legal Compliance. Buyer represents and warrants that it has complied and agrees that it will
comply with all applicable laws and regulations pertaining to the Products including, without
limitation, laws and regulations pertaining to transportation, storage, use, installation, resale,
export, and import of the products. Buyer shall have sole responsibility to obtain any
transportation, storage, use, export, import or other licenses or permits required under applicable
laws and regulations. Buyer acknowledges that it has received and is familiar with Myriant’s
labeling and literature concerning the products (including but not limited to instructions,
information, warnings and, if applicable, Material Safety Data Sheets) and agrees to, in a timely
manner, forward such information to its employees, agents, customers and others who will purchase,
handle, use, process, install, sell or be exposed to such products. Buyer agrees that it will not
knowingly sell or transfer the Products to persons using or proposing to use the Products for
purposes which are unsafe or prohibited by law. Nothing contained in these Terms shall be
construed to void or diminish any warnings, notices, instructions, or other information provided by
Myriant or its representatives or agents pertaining to product characteristics or the safe or
appropriate use, handling, storage, installation, transport or disposal of Products.

9. Applicable Law and Consent to Jurisdiction. Any claim or dispute arising hereunder hall be
governed by the laws of the Commonwealth of Massachusetts, irrespective of the choice of law rules
thereof. The United Nations Convention on Contracts for the International Sale of Goods is
expressly excluded. Any legal proceedings arising out of or relating in any way to these Terms
shall be commenced only in federal or state court located in the Commonwealth of Massachusetts and
each of the parties hereto consents to the jurisdiction of said courts in any such proceedings and
waives any objection to venue laid therein, provided, however, that nothing in this Section shall
be construed to preclude either party from asserting cross claims or third party claims in any
forum outside the Commonwealth of Massachusetts

10. Conflicting Terms. Any representations, warranties, conditions or indemnities or other terms
or conditions proposed or stated by Buyer in connection with any sale of products by Myriant or in
any purchase order or other document sent by Buyer which are in conflict with the foregoing are
expressly rejected by Myriant and waived by Buyer. The foregoing provision of this Section shall
not be supplemented, modified or amended unless agreed to in a writing signed by an officer of
Myriant.

 

			
	***	 	Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]